header-20.jpg
Translational Research

Preventing the Respiratory Failure Causing COVID-19 Mortality, Potent New Drugs Targeting Hyperinflammation

This project will develop highly potent novel drugs to prevent and cure acute respiratory distress syndrome, the rapid-onset life-threatening respiratory failure killing patients with COVID-19 and other respiratory viruses. Our drugs will save lives by targeting adipokine receptors responsible for the extreme overreaction of the body’s immune system and hyperactive inflammatory response that underpin rapid patient decline from respiratory failure.

Investigators

Dr Lisa Philp APCRC-Q, IHBI, QUT, TRI

Duration

2020 - 2022

Funding

Advance Queensland - Industry Research Fellowship - Mid Career $150,000
Industry partner and QUT contributions $150,000
Project funding total $300,000